Autosomal Dominant Pseudohypoaldosteronism Type 1 in an Infant with Salt Wasting Crisis Associated with Urinary Tract Infection and Obstructive Uropathy
Type 1 pseudohypoaldosteronism (PHA1) is a salt wasting syndrome caused by renal resistance to aldosterone. Primary renal PHA1 or autosomal dominant PHA1 is caused by mutations in mineralocorticoids receptor gene (NR3C2), while secondary PHA1 is frequently associated with urinary tract infection (UTI) and/or urinary tract malformations (UTM). We report a 14-day-old male infant presenting with severe hyperkalemia, hyponatremic dehydration, metabolic acidosis, and markedly elevated serum aldosterone level, initially thought to have secondary PHA1 due to the associated UTI and posterior urethral valves. His serum aldosterone remained elevated at 5 months of age, despite resolution of salt wasting symptoms. Chromosomal microarray analysis revealed a deletion of exons 3–5 in NR3C2 in the patient and his asymptomatic mother who also had elevated serum aldosterone level, confirming that he had primary or autosomal dominant PHA1. Our case raises the possibility that some patients with secondary PHA1 attributed to UTI and/or UTM may instead have primary autosomal dominant PHA1, for which genetic testing should be considered to identify the cause, determine future recurrence risk, and possibly prevent the life-threatening salt wasting in a subsequent family member. Future clinical research is needed to investigate the potential overlapping between secondary PHA1 and primary autosomal dominant PHA1. 1. Introduction Pseudohypoaldosteronism (PHA) is a disorder caused by aldosterone resistance with subsequent impaired sodium reabsorption and potassium excretion. The broad category of PHA includes PHA type 1 (PHA1) and PHA type 2 (PHA2, also known as Gordon’s syndrome or familial hyperkalemic hypertension). PHA1 is subdivided into primary (genetic) and secondary (or transient) forms. Primary PHA1 has two clinically and genetically distinct forms [1]: (1) the autosomal dominant or sporadic form (also called renal form), caused by mutations in the mineralocorticoid receptor (MR) coding gene NR3C2 [2] and (2) the autosomal recessive or generalized PHA1, which is caused by mutations in genes encoding subunits of the epithelial sodium channel [3]. The secondary (transient) PHA1 has been described in infants suffering from urinary tract malformations or urinary tract infections (UTI) or both [4–12]. We present the first case report of autosomal dominant PHA1 with an intragenic deletion of NR3C2, presenting with salt wasting crisis associated with UTI and posterior urethral valves, thereby mimicking secondary PHA1. 2. Case Presentation The male patient, the second child of
References
[1]
A. Hanukoglu, “Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects,” Journal of Clinical Endocrinology and Metabolism, vol. 73, no. 5, pp. 936–944, 1991.
[2]
D. S. Geller, J. Rodriguez-Soriano, A. Vallo Boado et al., “Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I,” Nature Genetics, vol. 19, no. 3, pp. 279–281, 1998.
[3]
S. S. Chang, S. Grunder, A. Hanukoglu et al., “Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1,” Nature Genetics, vol. 12, no. 3, pp. 248–253, 1996.
[4]
J. Rodriguez Soriano, A. Vallo, R. Oliveros, and G. Castillo, “Transient pseudohypoaldosteronism secondary to obstructive uropathy in infancy,” Journal of Pediatrics, vol. 103, no. 3, pp. 375–380, 1983.
[5]
T. L. Levin, S. J. Abramson, K. A. Burbige, J. P. Connor, C. Ruzal-Shapiro, and W. E. Berdon, “Salt losing nephropathy simulating congenital adrenal hyperplasia in infants with obstructive uropathy and/or vesicoureteral reflux—value of ultrasonography in diagnosis,” Pediatric Radiology, vol. 21, no. 6, pp. 413–415, 1991.
[6]
M. R. Perez-Brayfield, J. Gatti, E. Smith, and A. J. Kirsch, “Pseudohypoaldosteronism associated with ureterocele and upper pole moiety obstruction,” Urology, vol. 57, no. 6, p. 1178, 2001.
[7]
G. Bülchmann, T. Schuster, A. Heger, U. Kuhnle, I. Joppich, and H. Schmidt, “Transient pseudohypoaldosteronism secondary to posterior urethral valves—a case report and review of the literature,” European Journal of Pediatric Surgery, vol. 11, no. 4, pp. 277–279, 2001.
[8]
E. J. Schoen, S. Bhatia, G. T. Ray, W. Clapp, and T. T. To, “Transient pseudohypoaldosteronism with hyponatremia-hyperkalemia in infant urinary tract infection,” Journal of Urology, vol. 167, no. 2 I, pp. 680–682, 2002.
[9]
T. Watanabe, “Reversible secondary pseudohypoaldosteronism,” Pediatric Nephrology, vol. 18, no. 5, p. 486, 2003.
[10]
A. Belot, B. Ranchin, C. Fichtner et al., “Pseudohypoaldosteronisms, report on a 10-patient series,” Nephrology Dialysis Transplantation, vol. 23, no. 5, pp. 1636–1641, 2008.
[11]
R. Nandagopal, P. Vaidyanathan, and P. Kaplowitz, “Transient pseudohypoaldosteronism due to urinary tract infection in infancy: a report of 4 cases,” International Journal of Pediatric Endocrinology, vol. 2009, Article ID 195728, 4 pages, 2009.
[12]
R. Bogdanovi?, N. Staji?, J. Putnik, and A. Paripovi?, “Transient type 1 pseudo-hypoaldosteronism: report on an eight-patient series and literature review,” Pediatric Nephrology, vol. 24, no. 11, pp. 2167–2175, 2009.
[13]
L. Pujo, J. Fagart, F. Gary et al., “Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism,” Human Mutation, vol. 28, no. 1, pp. 33–40, 2007.
[14]
M. C. Zennaro and M. Lombès, “Mineralocorticoid resistance,” Trends in Endocrinology and Metabolism, vol. 15, no. 6, pp. 264–270, 2004.
[15]
D. S. Geller, J. Zhang, M. C. Zennaro et al., “Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1429–1436, 2006.
[16]
J. Rodriguez-Soriano, A. Vallo, R. Oliveros, and M. Ubetagoyena, “Normokalaemic pseudohypoaldosteronism is present in children with acute pyelopnephritis,” Acta Paediatrica, vol. 81, no. 5, pp. 402–406, 1992.
[17]
P. Sartorato, Y. Khaldi, A. L. Lapeyraque et al., “Inactivating mutations of the mineralocorticoid receptor in type I pseudohypoaldosteronism,” Molecular and Cellular Endocrinology, vol. 217, no. 1-2, pp. 119–125, 2004.
[18]
M. Bayer and S. Kutilek, “A hereditary form of pseudohypoaldosteronism may be manifested in the course of pyelonephritis,” Acta Paediatrica, vol. 82, no. 5, p. 504, 1993.